The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma

Chen, Su-Feng; Nieh, Shin; Jao, Shu-Wen; Wu, Min-Zu; Liu, Chia‐Lin; Chang, Yun-Ching; Lin, Yaoh‐Shiang

doi:10.1002/path.4226

Cited by 119 publications

(115 citation statements)

References 41 publications

(45 reference statements)

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…The prognostic significance of IL-33 was also examined. Several studies have shown that a high expression of IL-33 is associated with a poor prognosis in diverse cancers and may be a potential prognostic factor (23,25,26). However, opposing findings in different types of cancers have also been reported.…”

Section: Introductionmentioning

confidence: 86%

“…It has been shown that increased IL-33 expression may influence the survival in certain types of cancer patients (23,25,26,28). Hence, we also analyzed the relationship between IL-33 expression and clinical prognosis in CRC patients.…”

Section: The Predicating Significance Of Il-33 Level In the Adenomas mentioning

confidence: 99%

“…Moreover, IL-33 was reported to be associated with the invasion or metastasis of tumors in head and neck squamous cell carcinoma (23) and hepatocellular carcinoma (HCC) (24). The prognostic significance of IL-33 was also examined.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

Cui

Gundersen

et al. 2014

Cancer Immunol Immunother

108

View full text Add to dashboard Cite

Most sporadic colorectal cancers (CRCs) develop from preexisting adenomas. The transition from an adenoma to a CRC leads to disruption in cytokine secretion and immune imbalance.Interleukin-33 (IL-33) is a newly discovered proinflammatory cytokine belonging to the IL-1 cytokine family, and involved in the regulation of immune function and development of chronic colorectal inflammation and cancers. However, the activation of the IL33/ST2 axis alongside the colorectal adenoma-carcinoma sequence is poorly understood. Our aim is to evaluate the dynamics between the IL-33/ST2 axis and the human colorectal normaladenoma -carcinoma sequence. The expression of IL-33 in adenomas (n=50) determined by real-time PCR was significantly higher than that in the colorectal mucosa from normal individuals. The expression of IL-33 was also increased in CRCs (n=50) when compared to the normal control group. Significantly lower levels of IL-33 where found in the CRCs compared with the adenomas; moreover, the analysis revealed that a high IL-33 level was associated with a low dysplasia degree in the adenomas, as well as with a statistically nonsignificant increase of survival time in the CRC patients. The increased expression of IL-33 in adenomas/CRCs was confirmed by immunohistochemistry (IHC) which showed that IL-33 immunoreactivity was expressed in the adenomatous/cancerous epithelium, whereas it was undetectable in the normal controls. IHC also confirmed that the IL-33 receptor (ST2) is increased in tumor stromal cells. Double IHCs identified that IL-33 immunoreactivity was in the tumor stromal myofibroblasts and microvessels. In conclusion, the expression of IL-33 in the tumor microenvironment was dynamically altered along the colorectal adenomacarcinoma sequence; and may be a potential predictor for the progression of the adenoma to the CRC.3

show abstract

Section: Introductionmentioning

confidence: 86%

Section: The Predicating Significance Of Il-33 Level In the Adenomas mentioning

confidence: 99%

See 1 more Smart Citation

Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

Cui

Gundersen

et al. 2014

Cancer Immunol Immunother

108

View full text Add to dashboard Cite

show abstract

“…IL-33 has been reported as a potent inducer of Th2 immune responses as well as "alarmin" cytokine released from necrotic cells (Arshad et al, 2012;Lopetuso et al, 2012;Roy et al, 2014). Recently, some DOI:http://dx.doi.org/10.7314/APJCP.2014.15.8.3503 Correlations Between Serum IL33 and Tumor Development: a Meta-analysis researches reported that IL-33 is play important role in tumorigenesis and tumor progress (Chen et al, 2013;Jovanovic et al, 2014)Serum IL-33 may be a useful indicator for prognosis of tumor (Sun et al, 2011). In here, our meta-analysis included eight papers results shown that IL33 expression level is higher in tumor patients that in healthy people, so, there is a clinical value that IL-33 can be as a potential diagnostic for tumor patient.…”

Section: Discussionmentioning

confidence: 99%

“…We first found 723 studies which met inclusion criteria, after reviewing carefully, all of the eight papers (Sun et al, 2011;Naumnik et al, 2012;Zhang et al, 2012;Bergis et al, 2013;Chen et al, 2013;Gangemi et al, 2013;Hu et al, 2013;Santulli et al, 2013). were included into this meta-analysis.…”

Section: Generally Datamentioning

confidence: 99%

Correlations Between Serum IL33 and Tumor Development: a Meta-analysis

Chen

Huang²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Interleukin-33 (IL-33) has recently been implicated in tumor development. Methods: Data was obtained from PubMed, EMBASE, Clinical trial, Cochrane Library, Web of Science, CNKI and Wanfang databases. After quality assessment and data extraction, a meta-analysis was performed using Review Manager 5. 2 software. Results: There were eight documents included in this meta-analysis. The results showed IL33 levels to be higher in tumor patients than that in health people, but no correlations tumor stage, metastasis and survival time of tumor patients were evident. Conclusion: IL33 may be useful as an alarm factor in tumor detection and prognosis.

show abstract

IL‐33/ST2 as a potential target for tumor immunotherapy

Jiang

Lian

Ye³

et al. 2021

Eur J Immunol

View full text Add to dashboard Cite

IL‐33, a member of the IL‐1 family, was initially reported to be expressed constitutively in the nucleus of tissue‐lining and structural cells. However, upon tissue damage or injury, IL‐33 can be released quickly to bind with its cognate receptor ST2 in response to wound healing and inflammation and act as a DAMP. As a key regulator of Th2 responses, IL‐33/ST2 signal is primarily associated with immunity and immune‐related disorders. In recent years, IL‐33/ST2 signaling pathway has been reported to promote the development of cancer and remodel the tumor microenvironment by expanding immune suppressive cells such as myeloid‐derived suppressor cells or regulatory T cells. However, its role remains controversial in some tumor settings. IL‐33 could also promote effective infiltration of immune cells such as CD8+ T and NK cells, which act as antitumor. These dual effects may limit the clinical application to target this cytokine axis. Therefore, more comprehensive exploration and deeper understanding of IL‐33 are required. In this review, we summarized the IL‐33/ST2 axis versatile roles in the tumor microenvironment with a focus on the IL‐33‐target immune cells and downstream signaling pathways. We also discuss how the IL‐33/ST2 axis could be used as a potential therapeutic target for cancer immunotherapy.

show abstract

The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma

Cited by 119 publications

References 41 publications

Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer

Correlations Between Serum IL33 and Tumor Development: a Meta-analysis

IL‐33/ST2 as a potential target for tumor immunotherapy

Contact Info

Product

Resources

About